Fathom Research · SHARDACROP · Consolidated · as of 29 Aug 2026
Its real asset is not a factory but a stack of hard-won permits to sell generic crop chemicals across dozens of countries, and at 11 times earnings it is cheap, debt-free and cash-rich. The catch is that those chemicals are commodities, and their prices just put it through a year when profit fell ninety percent.
Sharda Cropchem sells generic (off-patent) agrochemicals, weedkillers, fungicides and insecticides, mainly by export. It does not own factories or invent molecules; it obtains the costly regulatory registrations to sell them abroad, buys the product from third-party makers, and sells it under its own brands. It also has a smaller non-agro trading business.
Sector
Commodities · Agrochemicals
Founded
2004
Head office
Mumbai
Revenue (FY26)
₹5,268 cr
Market cap
₹7,071 cr
Promoter holding
74.82%
Fathom view
Business
Asset-light, registration-led
Moat
Its stack of regulatory permits
Balance sheet
Debt-free, cash-generative
Earnings
Cyclical: fell 90% in FY24
Receivables
High, ~166 debtor days
Valuation
~11x earnings, cheap
Key questionIt is genuinely cheap and cash-rich. The one thing that decides it: is FY26's ₹681 crore profit a normal level, or a cyclical peak like FY22-23 that collapsed to ₹32 crore the very next year?
Sharda owns the hard-to-get regulatory permits to sell generic crop chemicals abroad, buys the chemicals cheaply from others, and sells them under its own brands, earning well but riding the commodity cycle.
Farmers everywhere need affordable crop protection, and most of the useful molecules are long off-patent, so the value is no longer in inventing them. It is in the right to sell them: every country demands its own expensive registration before a product can go on sale, and that paperwork is slow, costly and specialised. Sharda exists to do that unglamorous work at scale, holding a vast library of registrations and turning it into sales without ever owning a chemical plant.
Why has no one else already won? Because the registrations are a real barrier, even though the products are not. Anyone can buy the same generic chemical from the same Chinese factory, but they cannot legally sell it in Germany or Brazil without spending years and crores building the regulatory dossier Sharda already holds. That library, built over two decades, is genuinely hard to replicate quickly. What it does not do is protect the price: the chemical itself is a commodity, so when global oversupply or a destocking wave hits, prices fall for everyone holding registrations, Sharda included.
Where the edge is (and isn’t)
Strong
Registration moat
A two-decade library of costly, slow regulatory permits is genuinely hard to replicate and keeps most competitors out.
Strong
Asset-light model
No factories and no debt; it outsources manufacturing and owns the intangible permits, so capital needs are modest.
Strong
Cash generation
About 130% of profit became operating cash over five years, with free cash flow positive every year.
Weak
Commodity pricing
The products are generic chemicals, so prices are set by global supply and Chinese output, not by Sharda.
Weak
Earnings cyclicality
Profit fell more than 90% in FY24 on a destocking glut; the earnings are genuinely cyclical, not steady.
Mixed
Working capital
High receivables (~166 debtor days) and rising working-capital days tie up cash in the field.
Economic engine
Demand
Global crop protection
Farmers need affordable generics. Structural demand, but volumes and prices swing with the agrochemical cycle.
Revenue
Registrations x volume x price
Sales flow from the products it is registered to sell; the more registrations in more geographies, the wider the base.
Margins
Cyclical, ~10-20%
Set by the gap between the commodity price it buys at and the branded price it sells at. Collapsed to ~10% in FY24, back to ~20% in FY26.
Capital
Registrations, not plants
No factories. The main spend is building and renewing registrations (about ₹400 crore a year), which shows up as heavy amortisation.
Returns
30% ROCE, but cyclical
Good returns through a cycle, though the FY24 crash pulled the three-year average ROE down to the low teens.
Strategic position
Large innovator agrochem majors
Patent-holding multinationals that invent molecules and earn the premium
↓
Sharda Cropchem
An asset-light generic seller whose edge is a deep library of registrations across geographies
↓
Smaller generic traders
A tail of sellers without the registration depth or distribution reach
Why now
The stock is down about 17% over the past year and trades at roughly 11 times earnings, which looks cheap against a business earning 30% on capital with no debt. Part of that low multiple is the market's memory: FY24 was a shock, when a global agrochemical glut and Chinese price-dumping cut Sharda's profit by more than 90%. FY26 has bounced back hard, profit at a record ₹681 crore, but the market is refusing to pay up, unsure whether it is looking at a durable recovery or the next peak before the next trough. That doubt is the reason it is cheap.
What has to go right
The agrochemical cycle stays in recovery, keeping prices and margins healthy.
New registrations keep widening the product-geography base and the sales pool.
Chinese oversupply eases rather than returning to crush prices again.
Working capital and receivables stay under control as sales grow.
Why the business works
A record FY26: revenue ₹5,268 crore and profit ₹681 crore, recovering strongly from the FY24 slump.
Effectively debt-free, with interest cover about 50x and a healthy dividend payout.
About 130% of profit converting to operating cash over five years, positive free cash flow every year.
A deep, hard-to-replicate library of regulatory registrations across Europe, the Americas and beyond.
Why the thesis could fail
The products are commodities: profit fell more than 90% in FY24 on a global glut and Chinese price-dumping.
FY26's record profit may be a cyclical peak rather than a durable new level.
Reliance on third-party (largely Chinese) manufacturers for the actual chemicals.
High receivables (~166 debtor days) and rising working-capital days tie up cash and add risk.
Sector mental models
Industry structure
Fragmented, competitive
Many generic agrochemical sellers; differentiation is registrations and distribution, not the molecule.
Pricing power
Weak
Commodity products; global oversupply and Chinese pricing set the price.
Demand driver
Structural but cyclical
Steady farmer demand, but volumes and prices swing with destocking and weather cycles.
Cash conversion
Strong
About 130% of profit into operating cash over five years.
Balance sheet
Debt-free
No borrowings, interest cover about 50x, a healthy dividend payout.
One sentence to remember
You are buying a filing cabinet full of expensive permits, wrapped around a commodity. The permits are a real moat. The commodity is why the profit can fall 90% in a year.
01Company Overview
Sharda Cropchem sells crop chemicals, but the clever part is what it does not do. It does not build factories, and it does not invent new molecules. Instead it picks off-patent agrochemicals that anyone can legally copy, then does the one hard, expensive thing that keeps most people out: it obtains the regulatory registrations to sell each product in each country, thousands of them, across Europe, the Americas and beyond. Getting one registration takes years and a small fortune in testing and paperwork. Once Sharda holds them, it buys the actual chemical cheaply from third-party manufacturers, mostly in China and India, and sells it under its own labels through its distribution network. So the real asset is the filing cabinet, not the plant. That makes it asset-light, debt-free and cash-generative, and at 11 times earnings it looks cheap. Then you notice FY24, when profit fell from ₹342 crore to ₹32 crore in a single year. That is the whole story: a lovely moat wrapped around a commodity.
02Business Model & Industry
Unit of revenue: One registered product sold in one country. Each sale rests on a regulatory registration Sharda holds for that specific chemical in that specific market; the more registrations across more geographies, the wider the base of things it can sell. The margin on each is the spread between the commodity price it buys the chemical at and the branded price it sells at.
Model: A registration-and-distribution model. Sharda invests years and money to obtain regulatory approvals for off-patent agrochemicals, sources the products from third-party manufacturers, and sells them under its own labels through its distribution network. It also runs a smaller non-agro trading business in belts, dyes and dye intermediates.
The core: generic crop-protection products sold under Sharda's brands, backed by its registrations.
Non-agro (conveyor belts, dyes, intermediates)15%
A smaller, lower-key trading business that diversifies the mix.
Structure
Fragmented and competitive. Many companies sell generic agrochemicals; the differentiation is registrations and distribution, not the molecule itself.
Competitors
Patent-holding multinationals sit above, earning the innovation premium; below and alongside are other generic sellers and traders with varying registration depth.
Pricing power
Weak. The products are commodities, so global oversupply and Chinese output set the price. Sharda's edge is access to markets through registrations, not the ability to charge more.
Demand driver
Global demand for affordable crop protection: farmers needing herbicides, fungicides and insecticides. Steady in the long run, but cyclical in volume and price. (Structural in demand, cyclical in economics, with destocking waves and weather adding swings.)
TAM
A large global generic-agrochemical market across many geographies. Exact figures vary by source.
Penetration
Sharda participates market by market as it adds registrations; growth is widening the registered base more than a fixed pie shrinking.
Value-chain seat
It sits between the third-party manufacturer and the farmer, owning the market access (registrations) and the brand but not the production, so it captures a distribution-and-access margin exposed to the commodity price of what it sells.
Sharda is a genuinely clever, asset-light business: it owns a moat most people overlook, a deep library of expensive regulatory registrations, and monetises it with no factories, no debt, and strong cash generation. Through a cycle it earns healthy returns and converts profit to cash better than most. The honest limit is that the moat surrounds a commodity. Sharda controls access to markets but not the price of the chemical it sells, so when global supply floods, as it did in FY24, profit can fall off a cliff. This is a good business with a real edge, but a cyclical one, and its quality is better judged across a full cycle than by any single spectacular or dreadful year.
03Valuation Snapshot
Price
₹784
Market Cap
₹7,071 cr
52W High / Low
₹1,298 / ₹756
Stock P/E
11.3
computed price/EPS ≈ 11.3; cheap, but on possibly-cyclical earnings
P/B
2.3
EPS (TTM)
₹69.41
Book Value
₹348
Dividend Yield
1.91%
payout ~20-40%
04Financial Performance (5Y, in Crores)
FY22
₹3,580net ₹349 · 9.7%
FY23
₹4,045net ₹342 · 8.5%
FY24
₹3,163net ₹32 · 1%
FY25
₹4,320net ₹304 · 7%
FY26
₹5,268net ₹681 · 12.9%
RevenueNet profit₹ crore · % = PAT margin
05Key Ratios
ROE
23.2%
but 3Y average ~13% after the FY24 crash
ROCE
30.2%
through-cycle, dropped to 4% in FY24
Operating margin
~20%
cyclical; was ~10% in FY24
D/E
0.00
debt-free, interest cover ~50x
Cash conversion (5Y)
~129%
OCF / profit
Debtor days
~166
high; cash tied in receivables
06Cash Flow Forensics (in Crores)
FY24
OCF₹341FCF₹69
FY25
OCF₹604FCF₹211
FY26
OCF₹656FCF₹158
The cash flow is the strongest evidence for the bull case, and it holds up even in the bad year. Operating cash was ₹341 crore in FY24, when profit had collapsed to ₹32 crore, and ₹604 crore and ₹656 crore in the two recovery years, so over five years about 130% of reported profit became operating cash, with free cash flow positive every single year. That is a genuinely high-quality trait: the earnings are real money, not receivables dressed up as profit. The one nuance to understand is why free cash flow sits well below operating cash: Sharda spends roughly ₹400 crore a year on building and renewing registrations, which is its true form of capex. So the moat is not free; it is a continuous cash cost, and that spending, shown as heavy amortisation in the profit line, is what keeps the registration library alive.
07Growth
Sales CAGR (5Y)
17%
Sales CAGR (3Y)
9%
dragged by the FY24 slump
Profit CAGR (5Y)
24%
cyclical, not smooth
Profit growth (TTM)
49%
flattered by recovery off the FY24 trough
Cash conversion
~129%
08Management
Sharda Cropchem is controlled by the founding Bubna family, which holds about 74.8% and has kept that stake completely flat, so there is no self-dilution. The operating style is conservative and cash-focused: no debt, an asset-light model that avoids the capital sink of owning plants, and a steady dividend. Through the FY24 shock, management kept the balance sheet clean and cash coming in rather than chasing volume at any price, which is the right instinct in a cyclical commodity business. The fair things to watch are operational, not governance: the pace of new registrations (the growth engine), the level of receivables and working capital (which have crept up), and how disciplined the company stays on procurement when Chinese prices swing. This is a family business run to survive cycles, which is exactly what a commodity seller needs.
A deep, two-decade library of regulatory registrations across many countries
Distribution reach to sell branded generics into those markets
An asset-light, debt-free model that survives down-cycles cheaply
Long-standing sourcing relationships with third-party manufacturers
The moat is real but narrow, and it is a moat of access, not of price. The registration library is genuinely hard to replicate: a rival cannot legally sell the same generic in the same country without spending years and money to build the same paperwork. That keeps competitors out of Sharda's markets. What it cannot do is defend the margin, because the chemical inside the registered product is a commodity whose price is set by global supply. So the moat guards the doorway into each market; it does nothing to stop the commodity cycle from squeezing what Sharda earns once inside.
11The Story So Far
Sharda Cropchem has compounded over the long run but never in a straight line, because its earnings ride the agrochemical cycle. Revenue climbed from about ₹3,580 crore in FY22 to ₹5,268 crore in FY26, but profit tells the real story: ₹349 crore in FY22, ₹342 crore in FY23, then a brutal collapse to ₹32 crore in FY24 as a global glut and Chinese price-dumping crushed the market, followed by a recovery to ₹304 crore and then a record ₹681 crore in FY26. The stock has been volatile to match and is down about 17% over the past year, leaving it at roughly 11 times earnings. Through all of it the balance sheet stayed debt-free and the cash kept coming, which is the trait that separates Sharda from a typical commodity trader.
12Risks
Commodity cyclicality. Profit fell more than 90% in FY24 on a global glut; the earnings are genuinely cyclical, so FY26's record could be a peak. High.
China dependence. The actual chemicals are largely sourced from Chinese manufacturers, so supply and price swings there flow straight into Sharda's economics. Medium to High.
Receivables. Debtor days near 166 and rising working-capital days tie up cash and add collection risk in weaker markets. Medium.
Registration cost. Maintaining and growing the moat costs roughly ₹400 crore a year; if that spend stops earning, returns fall. Medium.
Regulatory / geographic. Changes to registration rules, tariffs or a key market could reshape the access advantage. Low to Medium.
13What the Headline Numbers Hide
✓
Promoter holding steady
Bubna family about 74.8%, unchanged; no self-dilution
✓
Debt and leverage
Debt-free, interest cover ~50x
✓
Cash conversion
About 130% of profit became operating cash over five years; FCF positive every year, even in FY24
!
Cyclical earnings
Profit fell >90% in FY24; FY26's record may be a peak, not a base
!
Working capital
Debtor days ~166 and working-capital days rising
✓
Earnings quality
Cash-backed and clean; the volatility is real cyclicality, not accounting games
Sector checklist
!
Cost / margin driver
Margin is the spread over commodity input; swings with global supply and Chinese pricing
✓
Cash-flow forensics
Unusually clean: ~130% cash conversion, FCF positive every year including the crash year
✓
Moat (registrations)
Deep, hard-to-replicate registration library across geographies
✓
Balance sheet
Debt-free, cash-generative, dividend-paying, well placed to ride cycles
!
Working capital / receivables
High debtor days (~166) and rising, a genuine watch-item
14Two-Engine Assessment
Earnings engine
The earnings engine is real and cash-backed, but it is a cyclical one, and that is the whole point. FY26 was a record, profit at ₹681 crore, and crucially the cash followed, with operating cash comfortably above profit and free cash flow positive even in the disastrous FY24. So the quality of the earnings is not in doubt; their steadiness is. The driver is the global agrochemical cycle, which swung from glut in FY24 to recovery in FY26, and Sharda cannot control it. The near-term question is not whether the profit is real (it is) but whether ₹681 crore is a mid-cycle level or a peak, and only the cycle, not the company, will answer that.
Multiple engine
The multiple is where the value and the caution meet. At about 11 times earnings, Sharda is cheap for a debt-free business earning 30% on capital through a cycle. If FY26 is close to a normal level, that is genuinely inexpensive. But 11 times a possibly-peak cyclical earnings number is the classic value-trap shape, the multiple looks lowest exactly when the earnings are highest, and buyers who anchored to FY22-23 profits found that out brutally in FY24. So the low multiple is not a free lunch; it is the market pricing in the risk that the cycle rolls over again.
My honest read: this is a better business than a first glance suggests, and cheaper than most things earning 30% on capital, but it is unmistakably cyclical, and cyclicals reward you for buying them scared, not comfortable. The registration moat is real, the balance sheet is pristine, and the cash conversion through the FY24 crash is genuinely impressive, proof the earnings are not paper. What I cannot tell you from the numbers is where in the cycle FY26's ₹681 crore sits. Buy it as a cheap, high-quality cyclical you are prepared to hold through the next trough, and the odds look sensible; buy it as if these earnings were steady, and FY24 is a warning about how that ends. I would be wrong to be cautious if new registrations and a longer up-cycle turn this into a structurally higher base rather than a peak.
15Mental-Model Lenses
The moat is the paperwork, not the factory
The thing to understand about Sharda is where its edge actually lives. It is not a chemist and not a manufacturer; its asset is a filing cabinet of regulatory registrations that took twenty years and a lot of money to build. A rival can buy the identical chemical from the identical factory and still be locked out of Germany or Brazil, because it does not hold the permit. That is a genuine, unusual moat. But be precise about what it protects: it guards the door into each market, not the price of what you sell once inside. The paperwork keeps competitors out; it does nothing to keep the commodity cycle from squeezing your margin.
A commodity wearing a moat
Ask why a business earning 30% on capital, debt-free, with a real barrier to entry, trades at 11 times earnings. The answer is FY24, when profit fell more than 90% in a single year because the chemical Sharda sells is a commodity, and global oversupply does not care how good your registrations are. That is the tension in one line: the access is defensible, the product is not. It is why you must value Sharda on mid-cycle earnings, not on FY26's record or FY24's collapse, and why the cheap-looking multiple is really the market's honest uncertainty about which of those two numbers is closer to normal.
Cash through the crash
Here is the detail that separates Sharda from an ordinary commodity trader, and it is worth pausing on. In FY24, the year profit cratered to ₹32 crore, operating cash was still ₹341 crore, and free cash flow stayed positive. Across five years about 130% of profit became cash. That tells you the earnings, however volatile, are real, and that the business can fund itself and pay dividends through a downturn without borrowing. It does not remove the cyclicality, nothing can, but it means the cycle bruises Sharda rather than breaking it. For a commodity business, surviving the trough in cash is most of the game.
17Summary
Sharda Cropchem is a clever, asset-light business with a moat most people miss: a deep library of expensive regulatory registrations that lets it sell generic crop chemicals across dozens of countries without owning a single factory. It is debt-free, converts profit to cash better than almost any commodity name (about 130% even through the crash year), and at 11 times earnings it looks cheap. The reason it is cheap is that the moat surrounds a commodity: profit fell more than 90% in FY24 when global supply flooded, and FY26's record ₹681 crore may be a cyclical peak rather than a durable base. So the real question is not the quality of the moat, which is genuine, but where in the cycle you are buying. Judge it across a full cycle, not on one great or one dreadful year. Not a buy or sell call. Do your own work and consult a SEBI-registered adviser.